APO Research
Talk to an analyst

APO RESEARCH · REPORT

GLP-1 Drug

Glucagon-like peptide-1 (GLP-1) drugs are peptide therapeutics that mimic or potentiate the actions of endogenous GLP-1 at the GLP-1 receptor, a class-B G-protein–coupled receptor expressed on pancreatic islet cells, in the gastrointestinal tract, and in the central and cardiovascular systems. Pharmacologically they restore or amplify the physiologic “incretin effect”: in hyperglycaemic states they enhance glucose-dependent insulin secretion from β-cells, suppress inappropriate glucagon from α-cells, slow gastric emptying early in treatment, and reduce appetite via hypothalamic and brainstem pathways. Because their insulinotropic action is glucose-dependent, GLP-1 receptor agonists (GLP-1RAs) have a low intrinsic risk of hypoglycaemia unless combined with insulin or insulin secretagogues, while their gastrointestinal effects (nausea, vomiting, diarrhoea) are class-typical, dose-related and mitigated by stepwise titration.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Glucagon-like peptide-1 (GLP-1) drugs are peptide therapeutics that mimic or potentiate the actions of endogenous GLP-1 at the GLP-1 receptor, a class-B G-protein–coupled receptor expressed on pancreatic islet cells, in the gastrointestinal tract, and in the central and cardiovascular systems. Pharmacologically they restore or amplify the physiologic “incretin effect”: in hyperglycaemic states they enhance glucose-dependent insulin secretion from β-cells, suppress inappropriate glucagon from α-cells, slow gastric emptying early in treatment, and reduce appetite via hypothalamic and brainstem pathways. Because their insulinotropic action is glucose-dependent, GLP-1 receptor agonists (GLP-1RAs) have a low intrinsic risk of hypoglycaemia unless combined with insulin or insulin secretagogues, while their gastrointestinal effects (nausea, vomiting, diarrhoea) are class-typical, dose-related and mitigated by stepwise titration.

At the molecular level the class spans two lineages. Exendin-based agents (e.g., exenatide and lixisenatide) derive from exendin-4 and are naturally DPP-4–resistant. Human-sequence analogues (e.g., liraglutide, semaglutide) and fusion constructs (e.g., dulaglutide) introduce substitutions or conjugations that protect the peptide from dipeptidyl peptidase-4 and renal clearance and, in long-acting variants, promote albumin binding or extend half-life through Fc fusion or PEGylation. Liraglutide carries a C16 fatty-acid side chain to bind albumin; semaglutide combines a DPP-4–resistant substitution with a C18 fatty-acid–spacer for strong albumin binding; dulaglutide fuses two GLP-1 analog moieties to a modified IgG4 Fc to slow elimination; exenatide extended-release incorporates the peptide into PLGA microspheres for weekly release; oral semaglutide employs the absorption enhancer SNAC to enable gastric uptake of an otherwise parenteral peptide. These structural strategies drive pharmacokinetics and clinical phenotype: short-exposure agents exert a proportionally larger post-prandial effect (via gastric emptying), while sustained-exposure agents have stronger fasting-glucose effects and smoother 24-hour control.

For clarity in product mapping, the marketed GLP-1RA portfolio covers human-sequence and exendin-based APIs across daily, weekly and oral modalities. Representative single-agent brands include exenatide immediate-release (Byetta) and extended-release (Bydureon/BCise), lixisenatide (Adlyxin/Lyxumia), liraglutide daily injection for diabetes (Victoza) and for weight management (Saxenda), dulaglutide weekly injection (Trulicity), semaglutide weekly injection for diabetes (Ozempic) and for weight management and cardiovascular risk reduction in appropriate populations (Wegovy), and semaglutide oral tablets (Rybelsus). Fixed-ratio combinations pair a GLP-1RA with basal insulin—insulin degludec + liraglutide (IDegLira; Xultophy) and insulin glargine + lixisenatide (iGlarLixi; Soliqua/Suliqua)—to streamline intensification in type 2 diabetes. Regional markets also include China domestic GLP-1RAs such as beinaglutide (short-acting, human-sequence GLP-1[7-36]) and PEG-loxenatide (weekly PEGylated exendin analogue). Dual- or multi-receptor incretin agonists exist but, by definition, sit outside the “GLP-1-only” class.

Indications in routine practice cluster into three labeled application domains. In type 2 diabetes (T2D), GLP-1RAs are used as an adjunct to diet and exercise as monotherapy when metformin is inappropriate, or in combination with oral agents and/or insulin when additional glycaemic control is needed; some agents have paediatric T2D labeling. In chronic weight management (Obesity), higher-dose liraglutide and semaglutide carry indications for adults with obesity or overweight with weight-related comorbidities, and certain labels extend to adolescents. In cardiovascular risk reduction (CV risk), specific products are approved to reduce major adverse cardiovascular events in adults with T2D and established atherosclerotic cardiovascular disease, and selected high-dose semaglutide carries a cardiovascular-risk reduction label in adults with established CVD who are overweight or obese. Risk-reduction labeling in chronic kidney disease for T2D populations is best treated as a T2D sub-label rather than a separate application domain. These labeled uses are product-specific; they should not be generalized across the entire class without reference to the individual label.

Mechanistically, receptor activation increases intracellular cAMP and engages PKA and Epac2 pathways, amplifying the β-cell exocytotic response to glucose, modulating β-cell gene expression and survival signals, and repressing α-cell glucagon in hyperglycaemia. In the gut, vagal and local effects slow gastric emptying at treatment initiation, which blunts post-prandial glucose excursions; this effect often attenuates with chronic dosing for long-acting agents. In the CNS, activation of POMC/CART neurons and downstream circuits decreases appetite and energy intake; peripheral effects on adipose tissue, liver and kidney contribute to weight loss and natriuresis. Cardiometabolic benefits observed in outcome studies likely reflect an integrated impact on weight, blood pressure, glycaemia, lipids and vascular inflammation rather than a single pathway.

Pharmacology and formulation determine dose cadence and “type.” In market segmentation, short-acting agents are those given daily or multiple times per day and are characterized by prominent post-prandial control; examples include exenatide immediate-release, lixisenatide and daily liraglutide. Long-acting agents deliver sustained exposure with weekly administration or, in the case of oral semaglutide, long pharmacodynamic activity despite daily dosing; examples include dulaglutide, semaglutide subcutaneous weekly, exenatide extended-release and PEG-loxenatide. Fixed-ratio combinations couple a GLP-1RA with basal insulin to produce complementary fasting and prandial control in a single daily injection. Oral semaglutide provides a non-injectable option but introduces administration rules—fasting state, limited water intake, and a wait period before food or other medications—that can affect real-world adherence.

Adherence is driven by device, titration and tolerability. Weekly autoinjectors lower injection burden and generally improve persistence compared with daily injectables, but gastrointestinal tolerability still requires careful uptitration. Oral semaglutide avoids needles yet trades that advantage for fasting-administration complexity; some patients prefer daily pens for simplicity once trained. Across the class, gradual dose escalation from a low introductory dose is central to minimizing GI symptoms. Most agents have low intrinsic hypoglycaemia risk when used without insulin or sulfonylureas; combination use often necessitates down-titration of the concomitant secretagogue or basal insulin as glycaemia improves. Class warnings include a contraindication in patients with personal or family history of medullary thyroid carcinoma or MEN2 for labels that carry a C-cell tumor warning, caution in patients with prior pancreatitis, and attention to gallbladder disease signals. Slowed gastric emptying can alter the absorption of co-administered oral drugs with a narrow therapeutic window, which warrants timing adjustments in practice. Rapid glycaemic improvement in susceptible patients may transiently worsen retinopathy and should be monitored.

From a development standpoint the class evolved from twice-daily exendin-based injections to weekly sustained-exposure analogues and, most recently, to high-dose weight-management regimens and an oral tablet formulation. Cardiovascular-outcomes programs transformed GLP-1RAs from pure glucose-lowering agents into cardiometabolic medicines with event-reduction labels for selected products and populations. Manufacturing has scaled from conventional peptide synthesis and sterile vialing to sophisticated autoinjector pens, PLGA microsphere encapsulation and tablet technologies that enable gastric uptake; these choices shape supply chains, dose flexibility and cost profiles.

In sum, GLP-1 drugs are a coherent but diverse class unified by a glucose-dependent incretin mechanism and differentiated by structure, exposure profile, dose form and label. The practical taxonomy that matters in clinical and market analysis is simple and serviceable: type by dosing profile (Short-acting; Long-acting; Fixed-ratio combo), modality by route (injection; oral), and application by labeled domain (T2D; Obesity; CV risk). Within that frame the choice of agent is a balance among glycaemic and weight targets, cardiovascular risk status, patient preference for frequency and route, and the operational realities of access, price and supply.

Selected research

Market Structure

Global GLP-1 Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025199 pages

Choose your research edition.

Industry ResearchGLP-1 Drug Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal GLP-1 Drug Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal GLP-1 Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GLP-1 Drug Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal GLP-1 Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

Glucagon-like peptide-1 (GLP-1) drugs are peptide therapeutics that mimic or potentiate the actions of endogenous GLP-1 at the GLP-1 receptor, a class-B G-protein–coupled receptor expressed on pancreatic islet cells, in the gastrointestinal tract, and in the central and cardiovascular systems. Pharmacologically they restore or amplify the physiologic “incretin effect”: in hyperglycaemic states they enhance glucose-dependent insulin secretion from β-cells, suppress inappropriate glucagon from α-cells, slow gastric emptying early in treatment, and reduce appetite via hypothalamic and brainstem pathways. Because their insulinotropic action is glucose-dependent, GLP-1 receptor agonists (GLP-1RAs) have a low intrinsic risk of hypoglycaemia unless combined with insulin or insulin secretagogues, while their gastrointestinal effects (nausea, vomiting, diarrhoea) are class-typical, dose-related and mitigated by stepwise titration.

At the molecular level the class spans two lineages. Exendin-based agents (e.g., exenatide and lixisenatide) derive from exendin-4 and are naturally DPP-4–resistant. Human-sequence analogues (e.g., liraglutide, semaglutide) and fusion constructs (e.g., dulaglutide) introduce substitutions or conjugations that protect the peptide from dipeptidyl peptidase-4 and renal clearance and, in long-acting variants, promote albumin binding or extend half-life through Fc fusion or PEGylation. Liraglutide carries a C16 fatty-acid side chain to bind albumin; semaglutide combines a DPP-4–resistant substitution with a C18 fatty-acid–spacer for strong albumin binding; dulaglutide fuses two GLP-1 analog moieties to a modified IgG4 Fc to slow elimination; exenatide extended-release incorporates the peptide into PLGA microspheres for weekly release; oral semaglutide employs the absorption enhancer SNAC to enable gastric uptake of an otherwise parenteral peptide. These structural strategies drive pharmacokinetics and clinical phenotype: short-exposure agents exert a proportionally larger post-prandial effect (via gastric emptying), while sustained-exposure agents have stronger fasting-glucose effects and smoother 24-hour control.

For clarity in product mapping, the marketed GLP-1RA portfolio covers human-sequence and exendin-based APIs across daily, weekly and oral modalities. Representative single-agent brands include exenatide immediate-release (Byetta) and extended-release (Bydureon/BCise), lixisenatide (Adlyxin/Lyxumia), liraglutide daily injection for diabetes (Victoza) and for weight management (Saxenda), dulaglutide weekly injection (Trulicity), semaglutide weekly injection for diabetes (Ozempic) and for weight management and cardiovascular risk reduction in appropriate populations (Wegovy), and semaglutide oral tablets (Rybelsus). Fixed-ratio combinations pair a GLP-1RA with basal insulin—insulin degludec + liraglutide (IDegLira; Xultophy) and insulin glargine + lixisenatide (iGlarLixi; Soliqua/Suliqua)—to streamline intensification in type 2 diabetes. Regional markets also include China domestic GLP-1RAs such as beinaglutide (short-acting, human-sequence GLP-1[7-36]) and PEG-loxenatide (weekly PEGylated exendin analogue). Dual- or multi-receptor incretin agonists exist but, by definition, sit outside the “GLP-1-only” class.

Read the full market overview

Indications in routine practice cluster into three labeled application domains. In type 2 diabetes (T2D), GLP-1RAs are used as an adjunct to diet and exercise as monotherapy when metformin is inappropriate, or in combination with oral agents and/or insulin when additional glycaemic control is needed; some agents have paediatric T2D labeling. In chronic weight management (Obesity), higher-dose liraglutide and semaglutide carry indications for adults with obesity or overweight with weight-related comorbidities, and certain labels extend to adolescents. In cardiovascular risk reduction (CV risk), specific products are approved to reduce major adverse cardiovascular events in adults with T2D and established atherosclerotic cardiovascular disease, and selected high-dose semaglutide carries a cardiovascular-risk reduction label in adults with established CVD who are overweight or obese. Risk-reduction labeling in chronic kidney disease for T2D populations is best treated as a T2D sub-label rather than a separate application domain. These labeled uses are product-specific; they should not be generalized across the entire class without reference to the individual label.

Mechanistically, receptor activation increases intracellular cAMP and engages PKA and Epac2 pathways, amplifying the β-cell exocytotic response to glucose, modulating β-cell gene expression and survival signals, and repressing α-cell glucagon in hyperglycaemia. In the gut, vagal and local effects slow gastric emptying at treatment initiation, which blunts post-prandial glucose excursions; this effect often attenuates with chronic dosing for long-acting agents. In the CNS, activation of POMC/CART neurons and downstream circuits decreases appetite and energy intake; peripheral effects on adipose tissue, liver and kidney contribute to weight loss and natriuresis. Cardiometabolic benefits observed in outcome studies likely reflect an integrated impact on weight, blood pressure, glycaemia, lipids and vascular inflammation rather than a single pathway.

Pharmacology and formulation determine dose cadence and “type.” In market segmentation, short-acting agents are those given daily or multiple times per day and are characterized by prominent post-prandial control; examples include exenatide immediate-release, lixisenatide and daily liraglutide. Long-acting agents deliver sustained exposure with weekly administration or, in the case of oral semaglutide, long pharmacodynamic activity despite daily dosing; examples include dulaglutide, semaglutide subcutaneous weekly, exenatide extended-release and PEG-loxenatide. Fixed-ratio combinations couple a GLP-1RA with basal insulin to produce complementary fasting and prandial control in a single daily injection. Oral semaglutide provides a non-injectable option but introduces administration rules—fasting state, limited water intake, and a wait period before food or other medications—that can affect real-world adherence.

Adherence is driven by device, titration and tolerability. Weekly autoinjectors lower injection burden and generally improve persistence compared with daily injectables, but gastrointestinal tolerability still requires careful uptitration. Oral semaglutide avoids needles yet trades that advantage for fasting-administration complexity; some patients prefer daily pens for simplicity once trained. Across the class, gradual dose escalation from a low introductory dose is central to minimizing GI symptoms. Most agents have low intrinsic hypoglycaemia risk when used without insulin or sulfonylureas; combination use often necessitates down-titration of the concomitant secretagogue or basal insulin as glycaemia improves. Class warnings include a contraindication in patients with personal or family history of medullary thyroid carcinoma or MEN2 for labels that carry a C-cell tumor warning, caution in patients with prior pancreatitis, and attention to gallbladder disease signals. Slowed gastric emptying can alter the absorption of co-administered oral drugs with a narrow therapeutic window, which warrants timing adjustments in practice. Rapid glycaemic improvement in susceptible patients may transiently worsen retinopathy and should be monitored.

From a development standpoint the class evolved from twice-daily exendin-based injections to weekly sustained-exposure analogues and, most recently, to high-dose weight-management regimens and an oral tablet formulation. Cardiovascular-outcomes programs transformed GLP-1RAs from pure glucose-lowering agents into cardiometabolic medicines with event-reduction labels for selected products and populations. Manufacturing has scaled from conventional peptide synthesis and sterile vialing to sophisticated autoinjector pens, PLGA microsphere encapsulation and tablet technologies that enable gastric uptake; these choices shape supply chains, dose flexibility and cost profiles.

In sum, GLP-1 drugs are a coherent but diverse class unified by a glucose-dependent incretin mechanism and differentiated by structure, exposure profile, dose form and label. The practical taxonomy that matters in clinical and market analysis is simple and serviceable: type by dosing profile (Short-acting; Long-acting; Fixed-ratio combo), modality by route (injection; oral), and application by labeled domain (T2D; Obesity; CV risk). Within that frame the choice of agent is a balance among glycaemic and weight targets, cardiovascular risk status, patient preference for frequency and route, and the operational realities of access, price and supply.

The global GLP-1 Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for GLP-1 Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for GLP-1 Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Asia Pacific market for GLP-1 Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for GLP-1 Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of GLP-1 Drug include Novo Nordisk, Eli Lilly, Sanofi, Teva, Jiangsu Hansoh Pharmaceutical, Huadong Medicine, Benemae Pharmaceutical, Tonghua Dongbao Pharma and Chia Tai-Tianqing Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global GLP-1 Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of GLP-1 Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents GLP-1 Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the GLP-1 Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

GLP-1 Drug Segment by Company

Novo Nordisk

Eli Lilly

Sanofi

Teva

Jiangsu Hansoh Pharmaceutical

Huadong Medicine

Benemae Pharmaceutical

Tonghua Dongbao Pharma

Chia Tai-Tianqing Pharmaceutical

AstraZeneca

GLP-1 Drug Segment by Type

Short-acting

Long-acting

GLP-1 Drug Segment by Indications

T2D

CV risk

Obesity

GLP-1 Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the GLP-1 Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of GLP-1 Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of GLP-1 Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of GLP-1 Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. GLP-1 Drug Industry Trends Table 2. GLP-1 Drug Industry Drivers Table 3. GLP-1 Drug Industry Opportunities and Challenges Table 4. GLP-1 Drug Industry Restraints Table 5. Global GLP-1 Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global GLP-1 Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global GLP-1 Drug Sales by Manufacturers (Sales (k PMT)) & (2021-2026) Table 8. Global GLP-1 Drug Sales Market Share by Manufacturers Table 9. Global GLP-1 Drug Average Sales Price (Net Price (USD/PMT)) of Manufacturers (2021-2026) Table 10. Global GLP-1 Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global GLP-1 Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global GLP-1 Drug Manufacturers, Product Type & Application Table 13. Global GLP-1 Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global GLP-1 Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Short-acting Table 17. Major Manufacturers of Long-acting Table 18. Global GLP-1 Drug Sales by Type 2021 VS 2025 VS 2032 (Sales (k PMT)) Table 19. Global GLP-1 Drug Sales by Type (2021-2026) & (Sales (k PMT)) Table 20. Global GLP-1 Drug Sales by Type (2027-2032) & (Sales (k PMT)) Table 21. Global GLP-1 Drug Sales Market Share by Type (2021-2026) Table 22. Global GLP-1 Drug Sales Market Share by Type (2027-2032) Table 23. Global GLP-1 Drug Revenue by Type 2021 VS 2025 VS 2032 (Sales (k PMT)) Table 24. Global GLP-1 Drug Revenue by Type (2021-2026) & (Sales (k PMT)) Table 25. Global GLP-1 Drug Revenue by Type (2027-2032) & (Sales (k PMT)) Table 26. Global GLP-1 Drug Revenue Market Share by Type (2021-2026) Table 27. Global GLP-1 Drug Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of T2D Table 29. Major Manufacturers of CV risk Table 30. Major Manufacturers of Obesity Table 31. Global GLP-1 Drug Sales by Application 2021 VS 2025 VS 2032 (Sales (k PMT)) Table 32. Global GLP-1 Drug Sales by Application (2021-2026) & (Sales (k PMT)) Table 33. Global GLP-1 Drug Sales by Application (2027-2032) & (Sales (k PMT)) Table 34. Global GLP-1 Drug Sales Market Share by Application (2021-2026) Table 35. Global GLP-1 Drug Sales Market Share by Application (2027-2032) Table 36. Global GLP-1 Drug Revenue by Application 2021 VS 2025 VS 2032 (Sales (k PMT)) Table 37. Global GLP-1 Drug Revenue by Application (2021-2026) & (Sales (k PMT)) Table 38. Global GLP-1 Drug Revenue by Application (2027-2032) & (Sales (k PMT)) Table 39. Global GLP-1 Drug Revenue Market Share by Application (2021-2026) Table 40. Global GLP-1 Drug Revenue Market Share by Application (2027-2032) Table 41. Global GLP-1 Drug Sales by Region: 2021 VS 2025 VS 2032 (Sales (k PMT)) Table 42. Global GLP-1 Drug Sales by Region (2021-2026) & (Sales (k PMT)) Table 43. Global GLP-1 Drug Sales Market Share by Region (2021-2026) Table 44. Global GLP-1 Drug Sales Forecasted by Region (2027-2032) & (Sales (k PMT)) Table 45. Global GLP-1 Drug Sales Forecasted Market Share by Region (2027-2032) Table 46. North America GLP-1 Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Sales (k PMT)) Table 47. North America GLP-1 Drug Sales by Country (2021-2026) & (Sales (k PMT)) Table 48. North America GLP-1 Drug Sales by Country (2027-2032) & (Sales (k PMT)) Table 49. Europe GLP-1 Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Sales (k PMT)) Table 50. Europe GLP-1 Drug Sales by Country (2021-2026) & (Sales (k PMT)) Table 51. Europe GLP-1 Drug Sales by Country (2027-2032) & (Sales (k PMT)) Table 52. Asia Pacific GLP-1 Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Sales (k PMT)) Table 53. Asia Pacific GLP-1 Drug Sales by Country (2021-2026) & (Sales (k PMT)) Table 54. Asia Pacific GLP-1 Drug Sales by Country (2027-2032) & (Sales (k PMT)) Table 55. South America, Middle East and Africa GLP-1 Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Sales (k PMT)) Table 56. South America, Middle East and Africa GLP-1 Drug Sales by Country (2021-2026) & (Sales (k PMT)) Table 57. South America, Middle East and Africa GLP-1 Drug Sales by Country (2027-2032) & (Sales (k PMT)) Table 58. Global GLP-1 Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global GLP-1 Drug Revenue by Region (2021-2026) & (US$ Million) Table 60. Global GLP-1 Drug Revenue by Region (2027-2032) & (US$ Million) Table 61. Global GLP-1 Drug Revenue Market Share by Region (2021-2026) Table 62. Global GLP-1 Drug Revenue Market Share by Region (2027-2032) Table 63. Novo Nordisk Company Information Table 64. Novo Nordisk Business Overview Table 65. Novo Nordisk GLP-1 Drug Sales (Sales (k PMT)), Price (Net Price (USD/PMT)), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Novo Nordisk GLP-1 Drug Product Portfolio Table 67. Novo Nordisk Recent Development Table 68. Eli Lilly Company Information Table 69. Eli Lilly Business Overview Table 70. Eli Lilly GLP-1 Drug Sales (Sales (k PMT)), Price (Net Price (USD/PMT)), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Eli Lilly GLP-1 Drug Product Portfolio Table 72. Eli Lilly Recent Development Table 73. Sanofi Company Information Table 74. Sanofi Business Overview Table 75. Sanofi GLP-1 Drug Sales (Sales (k PMT)), Price (Net Price (USD/PMT)), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Sanofi GLP-1 Drug Product Portfolio Table 77. Sanofi Recent Development Table 78. Teva Company Information Table 79. Teva Business Overview Table 80. Teva GLP-1 Drug Sales (Sales (k PMT)), Price (Net Price (USD/PMT)), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Teva GLP-1 Drug Product Portfolio Table 82. Teva Recent Development Table 83. Jiangsu Hansoh Pharmaceutical Company Information Table 84. Jiangsu Hansoh Pharmaceutical Business Overview Table 85. Jiangsu Hansoh Pharmaceutical GLP-1 Drug Sales (Sales (k PMT)), Price (Net Price (USD/PMT)), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Jiangsu Hansoh Pharmaceutical GLP-1 Drug Product Portfolio Table 87. Jiangsu Hansoh Pharmaceutical Recent Development Table 88. Huadong Medicine Company Information Table 89. Huadong Medicine Business Overview Table 90. Huadong Medicine GLP-1 Drug Sales (Sales (k PMT)), Price (Net Price (USD/PMT)), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Huadong Medicine GLP-1 Drug Product Portfolio Table 92. Huadong Medicine Recent Development Table 93. Benemae Pharmaceutical Company Information Table 94. Benemae Pharmaceutical Business Overview Table 95. Benemae Pharmaceutical GLP-1 Drug Sales (Sales (k PMT)), Price (Net Price (USD/PMT)), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Benemae Pharmaceutical GLP-1 Drug Product Portfolio Table 97. Benemae Pharmaceutical Recent Development Table 98. Tonghua Dongbao Pharma Company Information Table 99. Tonghua Dongbao Pharma Business Overview Table 100. Tonghua Dongbao Pharma GLP-1 Drug Sales (Sales (k PMT)), Price (Net Price (USD/PMT)), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Tonghua Dongbao Pharma GLP-1 Drug Product Portfolio Table 102. Tonghua Dongbao Pharma Recent Development Table 103. Chia Tai-Tianqing Pharmaceutical Company Information Table 104. Chia Tai-Tianqing Pharmaceutical Business Overview Table 105. Chia Tai-Tianqing Pharmaceutical GLP-1 Drug Sales (Sales (k PMT)), Price (Net Price (USD/PMT)), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Chia Tai-Tianqing Pharmaceutical GLP-1 Drug Product Portfolio Table 107. Chia Tai-Tianqing Pharmaceutical Recent Development Table 108. AstraZeneca Company Information Table 109. AstraZeneca Business Overview Table 110. AstraZeneca GLP-1 Drug Sales (Sales (k PMT)), Price (Net Price (USD/PMT)), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. AstraZeneca GLP-1 Drug Product Portfolio Table 112. AstraZeneca Recent Development Table 113. Key Raw Materials Table 114. Raw Materials Key Suppliers Table 115. GLP-1 Drug Distributors List Table 116. GLP-1 Drug Customers List Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. GLP-1 Drug Product Image Figure 2. Global GLP-1 Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global GLP-1 Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global GLP-1 Drug Sales (2021-2032) & (Sales (k PMT)) Figure 5. Global GLP-1 Drug Average Price (Net Price (USD/PMT)) & (2021-2032) Figure 6. Global Top 5 and 10 GLP-1 Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Short-acting Image Figure 9. Long-acting Image Figure 10. Global GLP-1 Drug Sales by Type (2021 VS 2025 VS 2032) & (Sales (k PMT)) Figure 11. Global GLP-1 Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global GLP-1 Drug Sales Market Share by Type (2021-2032) Figure 13. Global GLP-1 Drug Revenue by Type (2021 VS 2025 VS 2032) & (Sales (k PMT)) Figure 14. Global GLP-1 Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global GLP-1 Drug Revenue Market Share by Type (2021-2032) Figure 16. T2D Image Figure 17. CV risk Image Figure 18. Obesity Image Figure 19. Global GLP-1 Drug Sales by Application (2021 VS 2025 VS 2032) & (Sales (k PMT)) Figure 20. Global GLP-1 Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global GLP-1 Drug Sales Market Share by Application (2021-2032) Figure 22. Global GLP-1 Drug Revenue by Application (2021 VS 2025 VS 2032) & (Sales (k PMT)) Figure 23. Global GLP-1 Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global GLP-1 Drug Revenue Market Share by Application (2021-2032) Figure 25. North America GLP-1 Drug Sales and Growth Rate (2021-2032) & (Sales (k PMT)) Figure 26. North America GLP-1 Drug Sales Market Share by Country (2021-2032) Figure 27. U.S. GLP-1 Drug Sales and Growth Rate (2021-2032) & (Sales (k PMT)) Figure 28. Canada GLP-1 Drug Sales and Growth Rate (2021-2032) & (Sales (k PMT)) Figure 29. Mexico GLP-1 Drug Sales and Growth Rate (2021-2032) & (Sales (k PMT)) Figure 30. Europe GLP-1 Drug Sales and Growth Rate (2021-2032) & (Sales (k PMT)) Figure 31. Europe GLP-1 Drug Sales Market Share by Country (2021-2032) Figure 32. Germany GLP-1 Drug Sales and Growth Rate (2021-2032) & (Sales (k PMT)) Figure 33. France GLP-1 Drug Sales and Growth Rate (2021-2032) & (Sales (k PMT)) Figure 34. U.K. GLP-1 Drug Sales and Growth Rate (2021-2032) & (Sales (k PMT)) Figure 35. Italy GLP-1 Drug Sales and Growth Rate (2021-2032) & (Sales (k PMT)) Figure 36. Netherlands GLP-1 Drug Sales and Growth Rate (2021-2032) & (Sales (k PMT)) Figure 37. Asia Pacific GLP-1 Drug Sales and Growth Rate (2021-2032) & (Sales (k PMT)) Figure 38. Asia Pacific GLP-1 Drug Sales Market Share by Country (2021-2032) Figure 39. China GLP-1 Drug Sales and Growth Rate (2021-2032) & (Sales (k PMT)) Figure 40. Japan GLP-1 Drug Sales and Growth Rate (2021-2032) & (Sales (k PMT)) Figure 41. South Korea GLP-1 Drug Sales and Growth Rate (2021-2032) & (Sales (k PMT)) Figure 42. Southeast Asia GLP-1 Drug Sales and Growth Rate (2021-2032) & (Sales (k PMT)) Figure 43. India GLP-1 Drug Sales and Growth Rate (2021-2032) & (Sales (k PMT)) Figure 44. Australia GLP-1 Drug Sales and Growth Rate (2021-2032) & (Sales (k PMT)) Figure 45. South America, Middle East and Africa GLP-1 Drug Sales and Growth Rate (2021-2032) & (Sales (k PMT)) Figure 46. South America, Middle East and Africa GLP-1 Drug Sales Market Share by Country (2021-2032) Figure 47. Brazil GLP-1 Drug Sales and Growth Rate (2021-2032) & (Sales (k PMT)) Figure 48. South Africa GLP-1 Drug Sales and Growth Rate (2021-2032) & (Sales (k PMT)) Figure 49. Saudi Arabia GLP-1 Drug Sales and Growth Rate (2021-2032) & (Sales (k PMT)) Figure 50. Turkey GLP-1 Drug Sales and Growth Rate (2021-2032) & (Sales (k PMT)) Figure 51. Argentina GLP-1 Drug Sales and Growth Rate (2021-2032) & (Sales (k PMT)) Figure 52. UAE GLP-1 Drug Sales and Growth Rate (2021-2032) & (Sales (k PMT)) Figure 53. Egypt GLP-1 Drug Sales and Growth Rate (2021-2032) & (Sales (k PMT)) Figure 54. Chile GLP-1 Drug Sales and Growth Rate (2021-2032) & (Sales (k PMT)) Figure 55. Global GLP-1 Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global GLP-1 Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America GLP-1 Drug Revenue (2021-2032) & (US$ Million) Figure 58. North America GLP-1 Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe GLP-1 Drug Revenue (2021-2032) & (US$ Million) Figure 60. Europe GLP-1 Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific GLP-1 Drug Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific GLP-1 Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa GLP-1 Drug Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa GLP-1 Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. GLP-1 Drug Value Chain Figure 66. Manufacturing Cost Structure Figure 67. GLP-1 Drug Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Short-acting
  • Long-acting
Applications
  • T2D
  • CV risk
  • Obesity
Companies covered
  • Novo Nordisk
  • Eli Lilly
  • Sanofi
  • Teva
  • Jiangsu Hansoh Pharmaceutical
  • Huadong Medicine
  • Benemae Pharmaceutical
  • Tonghua Dongbao Pharma
  • Chia Tai-Tianqing Pharmaceutical
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global GLP-1 Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global GLP-1 Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global GLP-1 Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global GLP-1 Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global GLP-1 Drug Market Dynamics
  1. 2.1 GLP-1 Drug Industry Trends
  2. 2.2 GLP-1 Drug Industry Drivers
  3. 2.3 GLP-1 Drug Industry Opportunities and Challenges
  4. 2.4 GLP-1 Drug Industry Restraints
3 GLP-1 Drug Market by Manufacturers
  1. 3.1 Global GLP-1 Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global GLP-1 Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global GLP-1 Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global GLP-1 Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global GLP-1 Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global GLP-1 Drug Manufacturers, Product Type & Application
  7. 3.7 Global GLP-1 Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global GLP-1 Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 GLP-1 Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 GLP-1 Drug Tier 1, Tier 2, and Tier 3
4 GLP-1 Drug Market by Type
  1. 4.1 GLP-1 Drug Type Introduction
  2. 4.1.1 Short-acting
  3. 4.1.2 Long-acting
  4. 4.2 Global GLP-1 Drug Sales by Type
  5. 4.2.1 Global GLP-1 Drug Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global GLP-1 Drug Sales by Type (2021-2032)
  7. 4.2.3 Global GLP-1 Drug Sales Market Share by Type (2021-2032)
  8. 4.3 Global GLP-1 Drug Revenue by Type
  9. 4.3.1 Global GLP-1 Drug Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global GLP-1 Drug Revenue by Type (2021-2032)
  11. 4.3.3 Global GLP-1 Drug Revenue Market Share by Type (2021-2032)
5 GLP-1 Drug Market by Application
  1. 5.1 GLP-1 Drug Application Introduction
  2. 5.1.1 T2D
  3. 5.1.2 CV risk
  4. 5.1.3 Obesity
  5. 5.2 Global GLP-1 Drug Sales by Application
  6. 5.2.1 Global GLP-1 Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global GLP-1 Drug Sales by Application (2021-2032)
  8. 5.2.3 Global GLP-1 Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global GLP-1 Drug Revenue by Application
  10. 5.3.1 Global GLP-1 Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global GLP-1 Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global GLP-1 Drug Revenue Market Share by Application (2021-2032)
6 Global GLP-1 Drug Sales by Region
  1. 6.1 Global GLP-1 Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global GLP-1 Drug Sales by Region (2021-2032)
  3. 6.2.1 Global GLP-1 Drug Sales by Region (2021-2026)
  4. 6.2.2 Global GLP-1 Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America GLP-1 Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America GLP-1 Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe GLP-1 Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe GLP-1 Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific GLP-1 Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific GLP-1 Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa GLP-1 Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa GLP-1 Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global GLP-1 Drug Revenue by Region
  1. 7.1 Global GLP-1 Drug Revenue by Region
  2. 7.1.1 Global GLP-1 Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global GLP-1 Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global GLP-1 Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global GLP-1 Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America GLP-1 Drug Revenue (2021-2032)
  8. 7.2.2 North America GLP-1 Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe GLP-1 Drug Revenue (2021-2032)
  11. 7.3.2 Europe GLP-1 Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific GLP-1 Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific GLP-1 Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa GLP-1 Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa GLP-1 Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Novo Nordisk
  2. 8.1.1 Novo Nordisk Company Information
  3. 8.1.2 Novo Nordisk Business Overview
  4. 8.1.3 Novo Nordisk GLP-1 Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novo Nordisk GLP-1 Drug Product Portfolio
  6. 8.1.5 Novo Nordisk Recent Developments
  7. 8.2 Eli Lilly
  8. 8.2.1 Eli Lilly Company Information
  9. 8.2.2 Eli Lilly Business Overview
  10. 8.2.3 Eli Lilly GLP-1 Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly GLP-1 Drug Product Portfolio
  12. 8.2.5 Eli Lilly Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi GLP-1 Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi GLP-1 Drug Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Teva
  20. 8.4.1 Teva Company Information
  21. 8.4.2 Teva Business Overview
  22. 8.4.3 Teva GLP-1 Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Teva GLP-1 Drug Product Portfolio
  24. 8.4.5 Teva Recent Developments
  25. 8.5 Jiangsu Hansoh Pharmaceutical
  26. 8.5.1 Jiangsu Hansoh Pharmaceutical Company Information
  27. 8.5.2 Jiangsu Hansoh Pharmaceutical Business Overview
  28. 8.5.3 Jiangsu Hansoh Pharmaceutical GLP-1 Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Jiangsu Hansoh Pharmaceutical GLP-1 Drug Product Portfolio
  30. 8.5.5 Jiangsu Hansoh Pharmaceutical Recent Developments
  31. 8.6 Huadong Medicine
  32. 8.6.1 Huadong Medicine Company Information
  33. 8.6.2 Huadong Medicine Business Overview
  34. 8.6.3 Huadong Medicine GLP-1 Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Huadong Medicine GLP-1 Drug Product Portfolio
  36. 8.6.5 Huadong Medicine Recent Developments
  37. 8.7 Benemae Pharmaceutical
  38. 8.7.1 Benemae Pharmaceutical Company Information
  39. 8.7.2 Benemae Pharmaceutical Business Overview
  40. 8.7.3 Benemae Pharmaceutical GLP-1 Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Benemae Pharmaceutical GLP-1 Drug Product Portfolio
  42. 8.7.5 Benemae Pharmaceutical Recent Developments
  43. 8.8 Tonghua Dongbao Pharma
  44. 8.8.1 Tonghua Dongbao Pharma Company Information
  45. 8.8.2 Tonghua Dongbao Pharma Business Overview
  46. 8.8.3 Tonghua Dongbao Pharma GLP-1 Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Tonghua Dongbao Pharma GLP-1 Drug Product Portfolio
  48. 8.8.5 Tonghua Dongbao Pharma Recent Developments
  49. 8.9 Chia Tai-Tianqing Pharmaceutical
  50. 8.9.1 Chia Tai-Tianqing Pharmaceutical Company Information
  51. 8.9.2 Chia Tai-Tianqing Pharmaceutical Business Overview
  52. 8.9.3 Chia Tai-Tianqing Pharmaceutical GLP-1 Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Chia Tai-Tianqing Pharmaceutical GLP-1 Drug Product Portfolio
  54. 8.9.5 Chia Tai-Tianqing Pharmaceutical Recent Developments
  55. 8.10 AstraZeneca
  56. 8.10.1 AstraZeneca Company Information
  57. 8.10.2 AstraZeneca Business Overview
  58. 8.10.3 AstraZeneca GLP-1 Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca GLP-1 Drug Product Portfolio
  60. 8.10.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 GLP-1 Drug Value Chain Analysis
  2. 9.1.1 GLP-1 Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 GLP-1 Drug Production Mode & Process
  6. 9.2 GLP-1 Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 GLP-1 Drug Distributors
  9. 9.2.3 GLP-1 Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst